Dr. Fariba Navid, MD
Claim this profileChildren's Hospital Los Angeles
Expert in Recurrence
Expert in Tumors
29 reported clinical trials
40 drugs studied
About Fariba Navid, MD
Education:
- Earned an MD from Tulane Medical School, New Orleans, Louisiana.
- Completed a Clinical Fellowship in Pediatric Oncology at the National Cancer Institute, Bethesda, MD.
Experience:
- Serves as Assistant Director of the Clinical Trials Program and COG Phase I & Pilot Consortium at Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles (CHLA) since September 2016.
- Holds the position of Associate Professor of Clinical Pediatrics at the Keck School of Medicine, University of Southern California.
- Has extensive experience in research and pediatric early-phase drug development, including previous work at St. Jude Children's Research Hospital.
Area of expertise
1Recurrence
Global LeaderStage IV
Stage I
Stage II
2Tumors
Global LeaderStage IV
NTRK1 positive
NTRK positive
Affiliated Hospitals
Clinical Trials Fariba Navid, MD is currently running
Rapid Infusion of Dinutuximab
for Neuroblastoma
This trial aims to test if a cancer-fighting antibody can be given more quickly to children with high-risk neuroblastoma. The goal is to see if faster treatment is safe and effective, which could make it easier and less costly by allowing it to be done outside the hospital.
Recruiting5 awards Phase 4
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
More about Fariba Navid, MD
Clinical Trial Related1 year of experience running clinical trials · Led 29 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Fariba Navid, MD has experience with
- Larotrectinib
- Erdafitinib
- Olaparib
- Palbociclib
- Selpercatinib
- Tipifarnib
Breakdown of trials Fariba Navid, MD has run
Recurrence
Tumors
Osteosarcoma
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Fariba Navid, MD specialize in?
Fariba Navid, MD focuses on Recurrence and Tumors. In particular, much of their work with Recurrence has involved Stage IV patients, or patients who are Stage I.
Is Fariba Navid, MD currently recruiting for clinical trials?
Yes, Fariba Navid, MD is currently recruiting for 9 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Fariba Navid, MD has studied deeply?
Yes, Fariba Navid, MD has studied treatments such as Larotrectinib, Erdafitinib, Olaparib.
What is the best way to schedule an appointment with Fariba Navid, MD?
Apply for one of the trials that Fariba Navid, MD is conducting.
What is the office address of Fariba Navid, MD?
The office of Fariba Navid, MD is located at: Children's Hospital Los Angeles, Los Angeles, California 90027 United States. This is the address for their practice at the Children's Hospital Los Angeles.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.